Navigation Links
Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis
Date:7/10/2014

li>GSK's GSK-1278863A: Nearly one-third of nephrologists report high interest in this oral renal anemia product.
  • Shield Therapeutics' ST-10: Nearly a third of nephrologists report high interest in this oral ferric iron therapy.
  • Amgen's Velcalcetide: Should this intravenous therapy for secondary hyperparathyroidism (SHPT) receive FDA approval, nephrologists expect significantly higher usage in the dialysis versus the CKD non-dialysis (ND) setting.
  • OPKO Health's Rayaldee: While familiarity is low, over 40 percent of nephrologists report high interest in this oral Vitamin D therapy used to treat SHPT being tested in CKD stage 3 and stage 4 patients, after review of a product profile.
  • Comments from Decision Resources Group Director Rob Dubman:

    • "Physicians are recalling lower number of pills as one of Velphoro's primary messages from sales representatives. Not surprisingly, we have found that in this and other studies that delivery attributes are not as important compared with efficacy and safety attributes." 

    Additional Resources:

    A special report that is expected to publish later this month entitled The Impact of New Iron-Based Phosphate Binders on the Hyperphosphatemia Market will also help manufacturers understand why and how Velphoro and Keryx Pharmaceutical's Zerenex will be used, if Zerenex receives FDA approval later this year.

    About Decision Resources Group
    Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

    All company, brand, or product names contained in this document may be trademarks or registered trademarks of their
    '/>"/>

    SOURCE Decision Resources Group
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
    2. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
    3. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
    4. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
    5. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
    6. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
    7. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
    8. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
    9. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
    10. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
    11. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/1/2014)... 2014 Reportbuyer.com has added a new ... Lasers and Energy Devices Market Outlook to 2020, ... Brazil Aesthetic Lasers and Energy Devices Market ... GlobalData,s new report, "Brazil Aesthetic Lasers and ... market data on the Brazil Aesthetic Lasers and ...
    (Date:9/1/2014)... YORK , Sept. 1, 2014 ... market research report is available in its catalogue: ... 2014 - 2024 http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html ... (ADCs) are a new class of therapeutic agents, ... pharmaceutical companies. Generally addressed as the marriage of ...
    (Date:9/1/2014)... Reportlinker.com announces that a new market ... Drug Discovery Technologies - A Global Market Overview ... The development of new drugs for treating ... in addition to consuming a lot of time. ... involves the utilizing high-throughput screening of large chemical ...
    Breaking Medicine Technology:Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18Drug Discovery Technologies - A Global Market Overview 2Drug Discovery Technologies - A Global Market Overview 3Drug Discovery Technologies - A Global Market Overview 4Drug Discovery Technologies - A Global Market Overview 5Drug Discovery Technologies - A Global Market Overview 6Drug Discovery Technologies - A Global Market Overview 7Drug Discovery Technologies - A Global Market Overview 8Drug Discovery Technologies - A Global Market Overview 9Drug Discovery Technologies - A Global Market Overview 10Drug Discovery Technologies - A Global Market Overview 11
    ... YORK, Dec. 8, 2010 Reportlinker.com announces that ... its catalogue: Global Generic Pharmaceuticals ... The Global Generic Pharmaceuticals Industry Report ... evaluation of the Global Generic Pharmaceuticals Industry Report. ...
    ... Ill., Dec. 8, 2010 Life Spine announced today ... the OCTAVE Posterior Fusion System, which is intended for ... achieving fusion in conjunction with bone graft. The U.S. ... to the OCTAVE System last month. ...
    Cached Medicine Technology:Reportlinker Adds Global Generic Pharmaceuticals Industry Report 2Reportlinker Adds Global Generic Pharmaceuticals Industry Report 3Reportlinker Adds Global Generic Pharmaceuticals Industry Report 4Reportlinker Adds Global Generic Pharmaceuticals Industry Report 5Reportlinker Adds Global Generic Pharmaceuticals Industry Report 6Reportlinker Adds Global Generic Pharmaceuticals Industry Report 7
    (Date:9/2/2014)... AURO the enterprise Canadian ... the expansion of its leadership team with the appointment ... Officer. Liang joins AURO in conjunction with his current ... closely with the operations, product management and engineering teams ... as well as ensuring effective internal and external controls ...
    (Date:9/1/2014)... 02, 2014 Citrus Park Endodontics ... canal therapy based in Tampa, Florida, announced the launch ... helpful information aimed at making the patient experience at ... design featuring updated images that truly make the website ... website experience just as pleasant as our office experience ...
    (Date:9/1/2014)... 02, 2014 NAPW ... at Gibson Orthopedics Pain Treatment & Cardiology, ... Ms. Brinkley is recognized with this prestigious distinction ... most-recognized networking organization of women in the country, ... Association of Professional Women is a powerfully vibrant ...
    (Date:9/1/2014)... in an innovative Washington State University study of deadly ... involving black people. But when it came time to ... taking longer to pull the trigger against them than ... in the recent Journal of Experimental Criminology , ... the disproportionate number of ethnic and racial minorities shot ...
    (Date:9/1/2014)... 2014 Top10BestSEOHosting.com is a leading review ... top web hosting companies and announced that GreenGeeks, Arvixe ... August. , GreenGeeks ( http://www.greengeeks.com/cgi-bin/affiliates/clickthru.cgi?id=seohosts ) is one ... The company has a lot of useful products for ... products at low rates. , As one of ...
    Breaking Medicine News(10 mins):Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 2Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 3Health News:Citrus Park Endodontics Launches New Website to Better Serve Patients 2Health News:National Association of Professional Women Announces Laura Brinkley, Manager, Gibson Orthopedics Pain Treatment & Cardiology Clinic, a 2014 Professional Woman of the Year 2Health News:WSU 'deadly force' lab finds racial disparities in shootings 2Health News:WSU 'deadly force' lab finds racial disparities in shootings 3Health News:The Best Reseller Hosting Suppliers in August Released by Leading Review SiteTop10BestSEOHosting.com 2
    ... Bulgaria’s Agriculture Minister Nihat Kabil has revealed that ... bird flu. The bird was however not infected ... dangerous H5 virus. The dead swan was found ... was unable to say whether avian flu had ...
    ... expected in poultry during the course of 2006, according to ... take place // among human beings on a large scale, ... Governments have however been called upon to be prepared ... have been called upon to improve their surveillance where the ...
    ... end up losing as many as over 200 doctors, over the ... abortion. // The Catholic doctors who are from Queensland are of ... be deprived of his powers when it comes to deciding upon ... ,The AMA on the other hand is calling for ...
    ... meeting with Boston Scientific to talk about the repairs in ... held in 2001 with Schering-Plough // about problems with its ... to make any amendments. This provoked the FDA to withhold ... solve this problem Raul E. Cesan, the company's president and ...
    ... of the Teratology Society published a paper in the journal ... ,In this paper they said that overweight and ... develop medical problems at birth. ,This paper talked ... obese mothers. , It is stated that they ...
    ... closely monitored surveillance for patients with colon and rectal ... recurrence // compared to less aggressive strategy which is ... found that an intensified follow up of patients in ... diagnosis of cancer recurrence which could help in treatment ...
    Cached Medicine News:
    ... is an effective angina relief ... poor targets. Because it is ... the CO2 Heart Laser 2 ... timely operative decisions to revascularize ...
    Ultrasensitive TSH EIA Thyroid Function 025-BC-1003...
    TG (Ab) RIA Thyroid Function 014-HD 27.1 Thyroglobulin...
    ... anti-TG test kit is a solid phase ... It is designed for the quantitative measurement ... in serum or plasma. The microplate is ... controls and patient samples are pipetted into ...
    Medicine Products: